We review Immix Biopharma as it enters 2025, following the streamlining of its strategic priorities towards r/r ALA as the lead target indication for its CAR-T asset, NXC-201. The commencement of the US-based Phase Ib/II NEXICART-2 trial (n=40) in mid-2024 marked a major milestone, and we are encou

15 Jan 2025
Shifting the ALA treatment paradigm with CAR-T

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Shifting the ALA treatment paradigm with CAR-T
Immix Biopharma, Inc. (IMMX:NAS) | 0 0 0.0%
- Published:
15 Jan 2025 -
Author:
Jyoti Prakash, CFA | Arron Aatkar, PhD -
Pages:
17 -
We review Immix Biopharma as it enters 2025, following the streamlining of its strategic priorities towards r/r ALA as the lead target indication for its CAR-T asset, NXC-201. The commencement of the US-based Phase Ib/II NEXICART-2 trial (n=40) in mid-2024 marked a major milestone, and we are encou